Cisplatin + Etoposide +/- Concurrent ZD6474 in Previously Untreated Extensive Stage Small Cell Lung Cancer
Public ClinicalTrials.gov record NCT00613626. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized Double Blind Phase II Trial of Cisplatin Plus Etoposide With/Without Concurrent ZD6474 in Patients With Previously Untreated Extensive Stage Small Cell Lung Cancer: Hoosier Oncology Group LUN06-113
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
At this point in the treatment of extensive stage SCLC, we have reached a plateau in survival with conventional chemotherapy and newer regimens are greatly needed. It has been noted that patients with increased VEGF levels have a poorer prognosis. Anti-angiogenic agents hold significant promise in the treatment of patients with extensive stage SCLC. ZD6474, a new inhibitor of the VEGFR-2, has shown favorable action in NSCLC.
Study identification
- NCT ID
- NCT00613626
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 74 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 2008 (Type not available)
- Primary completion
- Aug 2015 (Actual)
- Completion
- Aug 2015 (Actual)
- Last update posted
- Feb 11, 2020
2008 – 2015
United States locations
- U.S. sites
- 19
- U.S. states
- 7
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Helen F. Graham Cancer Center | Newark | Delaware | 19713 | — |
| Northwestern University Feinberg School of Medicine | Chicago | Illinois | 60611 | — |
| Medical & Surgical Specialists, LLC | Galesburg | Illinois | 61401 | — |
| Cancer Care Center of Southern Indiana | Bloomington | Indiana | 47403 | — |
| Oncology Hematology Associates of SW Indiana | Evansville | Indiana | 47714 | — |
| Fort Wayne Oncology & Hematology, Inc | Fort Wayne | Indiana | 46815 | — |
| IN Onc/Hem Associates | Indianapolis | Indiana | 46202 | — |
| Indiana University Simon Cancer Center | Indianapolis | Indiana | 46202 | — |
| St. Vincent Hospital & Health Centers | Indianapolis | Indiana | 46206 | — |
| IU Health Arnett Cancer Center | Lafayette | Indiana | 47904 | — |
| Horizon Oncology Researcg | Lafayette | Indiana | 47905 | — |
| IU Health at Ball Memorial Hospital | Muncie | Indiana | 47303 | — |
| Monroe Medical Associates | Munster | Indiana | 46321 | — |
| Northern Indiana Cancer Research Consortium | South Bend | Indiana | 46601 | — |
| Providence Medical Group | Terre Haute | Indiana | 47802 | — |
| Methodist Cancer Center | Omaha | Nebraska | 68114 | — |
| Hematology Oncology Associates S.J., P.A. | Mount Holly | New Jersey | 08060 | — |
| Providence Portland Medical Center | Portland | Oregon | 97213 | — |
| Pennsylvania Oncology-Hematology Associates | Philadelphia | Pennsylvania | 19106 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00613626, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 11, 2020 · Synced Nov 9, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00613626 live on ClinicalTrials.gov.